Percepta® Genomic Sequencing Classifier
Reducing Unnecessary Invasive Procedures and Guiding Next Steps in Lung Cancer Evaluation

Veracyte estimates that up to 2 million people have lung nodules that are detected by CT scans every year. Determining whether these nodules are cancerous is often difficult and can lead to costly, invasive and often unnecessary procedures or to delayed treatment. The Percepta Genomic Sequencing Classifier (GSC) determines the risk of lung cancer to guide next steps for patients being evaluated for potentially cancerous lung nodules.

This next-generation test can help patients avoid unnecessary invasive procedures by identifying those with a low risk of having lung cancer, while helping to guide next intervention steps for patients it identifies as high risk. The Percepta GSC is used when results from bronchoscopy – a common, nonsurgical procedure to evaluate lung nodules – are inconclusive. Veracyte estimates that approximately 360,000 bronchoscopies are performed each year to evaluate lung nodules for cancer and that up to 60 percent of these produce inconclusive results.
The Percepta GSC is built on Veracyte’s RNA whole-transcriptome sequencing and machine-learning platform. The test uses novel “field of injury” science to identify genomic changes associated with lung cancer in current or former smokers by using a simple brushing of the person’s airway.

Data from a prospective clinical trial show that, among patients with an intermediate pre-test risk of lung cancer, the Percepta GSC had a high negative predictive value (91 percent) when it down-classified patients to “low risk” for cancer, and a 65 percent positive predictive value when it up-classified patients to “high risk” for cancer. The American College of Chest Physicians recommends that patients with a “low risk” of lung cancer undergo CT surveillance and that patients with a cancer risk of 65 percent or greater undergo surgical treatment.



Learn More About the Percepta Genomic Sequencing Classifier

Veracyte.com/Lung